Feature | Heart Valve Technology | December 12, 2018

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation

Delaware court rules Edwards Lifesciences’ Sapien 3 aortic valve infringes Boston Scientific patent

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation

December 12, 2018 — A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S. patent 8,992,608 is valid and that Edwards Lifesciences' Sapien 3 Aortic Valve infringes this patent. The court ruled that Edwards owes Boston Scientific $35 million in infringement damages through the end of 2016. Additional damages and interest incurred from 2017-2018 will be determined by the court in post-trial motions.

The jury also found that the Boston Scientific Lotus Aortic Valve System does not infringe Edwards' Spenser patents U.S. 7,510,575, U.S. 9,168,133, or U.S. 9,339,383.

In a statement, Edwards said it does not expect to pay the jury award since “earlier this year, the U.S. Patent and Trademark office determined that all asserted claims of the '608 patent were invalid.” Edwards plans to appeal the jury’s ruling on the Spenser valve patents.

The Lotus system features an adaptive sealing technology, which creates an external seal to prevent leakage around the valve known as paravalvular leak (PVL), which is a proven predictor of mortality.i,ii,iii The company anticipates the Lotus Edge Valve System will be commercialized in CE mark countries in Q1 2019 and in the U.S. in mid-2019, pending U.S. Food and Drug Administration (FDA) regulatory approval timelines.

The Lotus valve is one of two valve systems in the Boston Scientific structural heart portfolio. Boston Scientific currently offers the Acurate neo Aortic Valve System in key European markets and is also seeking a CE mark application for the next-generation valve system, the Acurate neo2, which it intends to commercialize during the first half of 2019.

UPDATE: On Jan. 15, 2019, Edwards and Boston Scientific reached an agreement to settle all outstanding patent disputes between the companies in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices and left atrial appendage closure devices. Any injunctions currently in place will be lifted. 

Under the terms of the agreement, Edwards has made a one-time payment to Boston Scientific of $180 million. No further royalties will be owed by either party under the agreement. All other terms remained confidential. 

For more information: www.bostonscientific.com, www.edwards.com

 

References

i. Kodali S.K., et al. Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med 2012; 366:1686-1695

ii. Tamburino C., et al. Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis. Circ. 2011;123:299.

iii. Abdel-Wahab M., et al. Aortic Regurgitation After Transcatheter Aortic Valve Implantation: Incidence and Early Outcome. Results from the German Transcatheter Aortic Valve Implantation Registry. Heart 2011;97:899-906.

Related Content

ACC Combines NCDR, Accreditation Into New Quality Summit
News | Cardiovascular Business | March 15, 2019
The American College of Cardiology’s first annual ACC Quality Summit, held March 13-15 in New Orleans, merges the NCDR...
Diagnostic and Interventional Cardiology Named 2019 Azbee Awards Finalist for Social Media
News | Cardiovascular Business | March 08, 2019 | Jeff Zagoudis, Associate Editor
Diagnostic and Interventional Cardiology (DAIC) was named a finalist in the Social Media Presence category for the 2019...
 FDA Commissioner Scott Gottlieb Announces Resignation
News | Cardiovascular Business | March 05, 2019 | Jeff Zagoudis, Associate Editor
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., resigned from his position March 5 after two...
Diagnostic and Interventional Cardiology Honored as Jesse H. Neal Awards Finalist

An example of the new transesophageal echo (TEE) visualization technology called TrueVue was shown at TCT 2018 for the first time. Philips’ new photo-realistic rendering is designed to offer a surgical view of cardiac structures to aid transcatheter procedural navigation.

News | Cardiovascular Business | February 25, 2019
Diagnostic and Interventional Cardiology has been recognized as a finalist in the Jesse H. Neal Awards for the third...
GE to Postpone Healthcare IPO Following Biopharmaceutical Business Sale
News | Cardiovascular Business | February 25, 2019 | Jeff Zagoudis, Associate Editor
GE Healthcare announced Feb. 25 the sale of its biopharmaceutical business to Danaher, and GE Chairman and CEO Larry...
Medical Bills Financially Burden Almost Half of Cardiovascular Disease Patients
News | Cardiovascular Business | February 11, 2019
Over 45 percent of adult atherosclerotic cardiovascular disease (ASCVD) patients suffer financial hardship related to...
Researchers raised the question whether an economic benefit should be assessed in FDA reviews. A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters.

A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters. Researchers raised the question whether an economic benefit should be assessed in FDA reviews. 

Feature | Cardiovascular Business | January 14, 2019 | Philip Jacobs, DPhil, Ilke Akpinar, M.D., Thanh Nguyen, M.D., Ph.D., Rupinder Sandhu, M.D., and Lars Thording Ph.D.
In an age when everything in medicine is now looked at though a cost vs. benefit analysis and U.S.
GE Submits Initial Public Offering Paperwork for Healthcare Division
News | Cardiovascular Business | December 19, 2018
As part of its plans to spin off its healthcare division into a separate company, GE reportedly submitted the paperwork...
Affordable Care Act Ruled Unconstitutional in Texas Federal Court
News | Cardiovascular Business | December 17, 2018
A judge of the Federal District Court for the Northern District of Texas ruled the Affordable Care Act (ACA)...
Average Age of U.S. Cardiologists Up While Income is Down
News | Cardiovascular Business | October 25, 2018
Overall cardiology compensation has dropped for the first time since 2014, according to the sixth annual Cardiovascular...
Overlay Init